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Abstract
Aim of the present study was to investigate the feasibility and long-term results of focused
radioguided parathyroidectomy using a "low" 37 MBq (1 mCi) 99mTc-sestamibi dose protocol
compared to conventional "high 740 MBq (20 mCi) 99mTc-sestamibi dose protocol" in patients with
primary hyperparathyroidism (PHPT). The data of focused radioguided surgery obtained in a group
of 320 consecutive PHPT patients with high probability of the presence of a solitary parathyroid
adenoma (PA) were studied. All patients underwent preoperative imaging work-up of double-
tracer  99mTc-pertechnetate/99mTc-sestamibi subtraction parathyroid scintigraphy (Sestamibi
scintigraphy) and high resolution neck ultrasound (US). In 301/320 patients (96.6%) focused
minimally invasive radioguided surgery was successfully performed by administering a "low" 37 MBq
(1 mCi) 99mTc-sestamibi dose in the operating room 10 minutes before operation. No major
intraoperative complications were recorded. Focused radioguided surgery required a mean time
of 32 min and a mean hospital stay of 1.2 days. Local anesthesia was applied in 75 patients, 66 of
whom (88%) were patients older than 65 years with comorbidities contraindicating general
anesthesia. No case of persistent or recurrent PHPT was observed during post-surgical follow-up
(range = 18–70 months; mean +/- SD = 15.3 +/- 9.1 months). Radiation exposure dose to the
operating surgeon was 1.2 μSi/hour with the "low 37 MBq (1 mCi) 99mTc-sestamibi dose", and less
than 1.0 μSi/hour for the other operating-room personnel. Focused low dose radioguided
parathyroidectomy is a safe and effective means to localize parathyroid adenomas in patients
affected by solitary PA thus reducing by 20 fold the radiation exposure dose to the patients and
operating room personnel.
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Background
The surgical approach to patients with primary hyperpar-
athyroid (PHPT) has moved from bilateral neck explora-
tion (BNE) to minimally invasive operative alternatives of
endoscopic or focused radioguided surgery.
The popularity of the focused surgical approach has
occurred as a result of technical improvements in surgical
practice by the introduction of the endoscope, the intra-
operative gamma probe, and the availability of rapid,
intraoperative measurements of "quick" parathyroid hor-
mone (QPTH). In a worldwide survey published in 2002,
more than half of endocrine surgeons favored a mini-
mally invasive approach to PHPT patients with a high
likelihood of a solitary parathyroid adenoma (PA) as the
etiology of their disease [1].
In contrast to the more traditional approach of BNE, the
minimally invasive focused approach requires rapid and
accurate preoperative localization:
• to establish the etiology of PHPT;
￿ to precisely localize PA (orthotopic or ectopic position,
deepness, etc);
￿ to distinguish the presence of 99mTc-sestamibi-avid thy-
roid nodules mimicking PA and which may result in false
positive intraoperative probe localization [3,4].
The present study details our experience with focused
minimally invasive parathyroidectomy in a group of 300
consecutive patients using the "low 37 MBq (1 mCi) ses-
tamibi protocol" and the intraoperative gamma probe.
Materials and methods
Three-hundred and twenty consecutive patients with clin-
ically and biochemically proven PHPT entered the study.
There were 207 females and women and 113 men, mean
age 55.3 years (range 16–83 years). Fifty-five, (55) of these
patients had undergone in other centers previous thyroid
or unsuccessful parathyroid surgery. The following inclu-
sion criteria were used for focused radioguided, mini-
mally invasive, parathyroidectomy: (a) the evidence at
double-tracer 99mTc-pertecnetate/99mTc-sestamibi subtrac-
tion (99mTc-sestamibi) scintigraphy of a solitary PA; (b)
unambiguous  99mTc-sestamibi uptake in the suspected
PA; (c) absence of other 99mTc-sestamibi-avid nodules; (d)
absence of history of familial hyperparathyroidism or
multiple endocrine neoplasia (MEN); or (e) no prior neck
irradiation.
One hundred and seven patients were excluded from
focused minimally invasive parathyroidectomy for not
meeting these inclusion criteria and were offered tradi-
tional BNE.
Preoperative imaging consisted of a single-session 99mTc-
sestamibi scan and high resolution neck ultrasound (US)
as previously described [3,5-8]. In patients with concord-
ant 99mTc-sestamibi/US findings (both positive or nega-
tive) no further imaging was performed, while in
discrepant cases (99mTc-sestamibi positive but US nega-
tive) a 99mTc-sestamibi tomographic (SPECT) examina-
tion (n. = 111 patients) was also obtained to evaluate
possible ectopic or deep-seated PA located in the para-ret-
roesophageal/para-retrotracheal space. SPECT was
obtained immediately after the completion of planar
99mTc-sestamibi imaging and as a result, 99mTc-sestamibi
re-injection was not necessary, avoiding additional radia-
tion exposure. The scintigraphic studies required approxi-
mately 1 hour (40 minutes for the planar and 20 minutes
for SPECT imaging) to complete).
The scintigraphic images were interpreted by two nuclear
medicine physicians; in cases of disagreement the final
impression was reached by consensus. In patients with a
normal thyroid gland confirmed both at 99mTc-pertech-
netate scintigraphy and neck US, a single focus of 99mTc-
sestamibi uptake was considered to be consistent with a
solitary PA while in patients in whom at least two foci of
99mTc-sestamibi uptake were demonstrated multiple ade-
nomas were reported. In patients with concomitant 99mTc-
sestamibi positive thyroid nodules, neck US, 99mTc-pertec-
netate thyroid scintigraphy was used to distinguish PA
from the sestamibi-avid thyroid nodule(s).
Planar sestamibi scintigraphy was acquired by a large-
field-of-view (LFOV) gamma camera (Orbiter, 7500, Sie-
mens, Hoffman Estates, IL or E-CAM, Siemens, Hoffman
Estates, IL) equipped with a parallel hole, low-energy,
high resolution collimator. Images were stored in a 128 ×
128 matrix and processed using a dedicated computer.
Tomographic sestamibi SPECT acquisition was performed
by a dual-head gamma camera (Axis, Picker International,
Cleveland, Ohio or E-CAM, Siemens, Hoffman Estates, IL)
equipped with a couple of parallel-hole low-energy ultra-
high-resolution collimators. The following parameters
were adopted: elliptical orbit, 120 (64 × 2) steps, 30 sec
per step, 64 × 64 matrix. Images were reconstructed using
a Butterworth filter, cut-off 0.45–0.65, order 5–8, and
processed using a dedicated computer: three-dimensional
(3D) analysis and £D rendering imaging was also
obtained.
Neck ultrasound was performed using high resolution,
7.5–12.5 MHz, transducer (Technos, Esaote, Italy). Longi-
tudinal and axial neck scans were obtained from the angleInternational Seminars in Surgical Oncology 2006, 3:30 http://www.issoonline.com/content/3/1/30
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of the mandible to the sternal notch. The PA was identi-
fied on gray-scale imaging as a hypo-echoic nodule well
distinct from the thyroid gland.
After operation, the surgeon was asked to judge the utility
of the gamma probe during operation using a 4-point
scale of "not valuable", "slightly valuable", "definitely val-
uable", and "very valuable".
The intraoperative technique used in our center for mini-
mally invasive radioguided surgery is outlined in Table 1.
A hand-held commercially available collimated gamma
probe (Scintiprobe MR 100, Pol.hi.tech., Italy) was used.
Intraoperative QPTH was measured by immunochemolu-
minescent assay (Liason, Byk Gulden, Italy). A fall of 50%
or more in PTH levels 10 minutes after PA removal in
comparison with baseline pre-excision value was consid-
ered indicative of a successful parathyroidectomy. Addi-
tional blood samples for QPTH measurement were
obtained in patients with multigland disease after
removal of any hyperfunctioning parathyroid gland.
All operations were performed by the same surgeon
(M.R.P.). Post-surgical follow-up ranged 18–70 months,
mean +/- SD = 15.3 +/- 9.1 months.
All patients received clinical and laboratory surveys 1
month after surgery and subsequently every 2–3 months,
thereafter.
Data are expressed as mean +/- 1 standard deviation (SD).
Mean values were compared using Student's t test. P val-
ues lower than 0.05 were considered significant.
Results
Charactheristics of our patient population are resumed in
Table 2.
On the basis of preoperative 99mTc-sestamibi scintigraphy
and high resolution neck US results, focused minimally
invasive parathyroidectomy was offered to 320 patients,
and was successfully performed in 309 (96.6%). Figure 1
shows an example of double-tracer planar and SPECT ses-
tamibi scintigraphy.
In 11 patients BNE was performed: in 2 patients because
of suspected parathyroid carcinoma, in 4 patients because
of a persistently elevated QPTH levels after removal of the
preoperatively visualized PA (in all these 4 cases a second
PA was found during subsequent BNE), and in 4 because
of a technical difficulties due to either unusual position
and/or large size precluded minimally invasive parathy-
roidectomy.
Considering the group of 309 patients in whom focused
minimally invasive parathyroidectomy was successfully
performed, the surgeon judged the gamma probe as
"slightly valuable" in 29 cases (9.4%), "definitely valua-
ble" in 203 cases (65.7%) and "very valuable" in 77 cases
(24.9%). The probe was critical in identifying 21 ectopic
PAs located in the mediastinum, 2 ectopic PAs located at
Table 1: Characteristics of our patients population affected by primary hyperparathyroidism
Patients in whom focused miminally 
invasive parathyroidectomy was planned
Patients in whom bilateral neck 
exploration was planned
Total patients number 320 107
Solitary PA and normal thyroid gland* 320 0
Solitary PA and nodular goitre* 0 51
Parathyroid multigland disease 0 27
Negative sestamibi scan 0 21
History of familial hyperparathyroidism 0 3
History of multiple endocrine neoplasia (MEN) 0 4
History of neck irradiation 0 1
Previous thyroid/parathyroid surgery 75 18
Mean (and range) levels of preoperative serum 
calcium (mg/dl)
12.1 (10.6 – 13.8) 12.2 (10.6 – 13.7)
Mean (and range) levels of preoperative serum 
PTH (pg/ml)
196 (84 – 351) 221 (91 – 336)
Mean (and range) operating time, minutes 32 (15 – 58) 78 (52 – 107)
Mean (and range) hospital stay, days 1.2 (1 – 2) 2.5 (2 – 5)
Mean (and range) post-surgical follow-up, 
months
15.3 (18 – 70) 15.9 (18 – 83
Recurrent hyperparathyroidism 0 cases 4 cases; 3.7% (all multigland disease at first 
diagnosis)
PA = parathyroid adenoma
*Thyroid gland evaluated by thyroid scan and ultrasoundInternational Seminars in Surgical Oncology 2006, 3:30 http://www.issoonline.com/content/3/1/30
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the carotid bifurcation, and 24 PAs located deep in the
neck in the para-retroesophageal/para-retrotracheal space.
Mean operating time was 32 minutes (range, 15–64) and
the mean hospital stay of 1.2 days (range, 1–2 days). Local
anesthesia was successfully performed in 75 patients, the
majority of whom (n. = 66; 88%) were older than 65 years
with comorbidities contraindicating general anesthesia.
No major surgical complication (laryngeal nerve palsy,
permanent hypoparathyroidism) were noted. Transient
hypocalcemia was observed in 8.6% of cases. A small 1.5
to 2 cm skin incision was sufficient to perform focused
minimally invasive radioguided parathyroidectomy. It is
worth noting that focused parathyroidectomy was suc-
cessfully performed in 42/55 patients (76.4% of cases)
with recurrent hyperpararthyroidism, prior thyroid sur-
gery or previously unsuccessful parathyroid surgery.
The mean PA to background (P/B) uptake ratio was high
(2.6); and the mean PA to thyroid (P/T) ratio was rela-
tively elevated (1.5). Of note, normal parathyroid glands
intraoperatively identified by the probe did not demon-
strate 99m Tc-sestamibi accumulation over background.
In the group of patients in whom SPECT was performed,
it is worth noting that in 39 cases SPECT analysis correctly
suggested a deep location of PA which was confirmed at
operation.
The mean weight of the excised solitary PA by MIRS was
990 +/- 310 mg. The parathyroid glands removed in
patients with multiple gland disease were significantly
smaller (mean weight = 530 +/- 420 mg; p < 0.05).
Mean radiation exposure in the operating room after the
injection of a low 37 MBq (1 mCi) of 99mTc-sestamibi
dose, was 1.2 μSi/hour for the surgeon and less than 1.0
μSi/hour for other operating suite personnel. Present
European Atomic Energy Community (EURATOM) rec-
ommends a radiation dose to the general public of < 1000
μSi/year, using this regulatory threshold, an endocrine
surgeon and support operating room staff could perform
approximately 1000 – 1500 focused parathyroidectomies
per year with the "low 37 MBq (1 mCi) of 99mTc-sestamibi
dose" protocol before reaching the EURATOM recom-
mended dose for the general population.
Discussion
Tibblin et al. made the first attempt to perform a limited
neck exploration in PHPT patients in the early '80s [9].
They performed a unilateral neck exploration removing
the PA with biopsy of the ipsilateral parathyroid gland in
an attempt to identify the presence of glandular hyperpla-
sia. More recently minimally invasive endoscopic [10,11]
and gamma probe-guided [3-8,12-14] approaches were
developed for focused minimally invasive parathyroidec-
tomy.
The development and popularity of focused minimally
invasive, parathyroidectomy, has occurred because of (i)
the improvement in preoperative localization imaging
mainly related to 99mTc-Sestamibi scintigraphy [15-20]
and (ii) the introduction in clinical practice of intraoper-
ative QPTH measurements. Successful focused minimally
invasive parathyroidectomy requires strict attention to
patient selection criteria that include:
(a) high likelihood of a solitary PA demonstrated at pre-
operative 99mTc-sestamibi/US imaging;
(b) unambiguous 99mTc-sestamibi uptake in the PA;
(c) absence of other 99mTc-sestamibi avid thyroid nodules.
Using these selection criteria about two thirds of all PHPT
patients can be offered focused minimally invasive para-
throidectomy as an alternative to BNE [3-8,12-14].
Thus, the success of focused parathyroidectomy is
dependent upon precise preoperative localization of a sol-
itary PA. In this regard, there is evidence that the combi-
Table 2: Focused radioguided surgery using the 'low sestamibi dose' procedure.
(a) QPTH levels measured just before intervention and 10 min after PA removal
(b) 37 MBq (1 mCi) of 99mTc-sestamibi injected in the operating room 10 min before intervention
(c) prior to surgery, patient's neck scanned with the probe to individualize the PA
(d) a transverse midline neck 1.5 – 2 cm access, 1 cm above the sternal notch, is performed
(e) probe is repeatedly inserted through the wond guiding the surgeon to the PA.
(f) radioactivity is measured on the PA, thyroid gland and background
(g) radioactivity is measured on the ex vivo PA
(h) radioactivity is checked on the empty operating basin
(i) tissue ratios are calculated (P/B, P/T)
QPTH = quick parathyroid hormone
BNE = bilateral neck exploration
PA = parathyroid adenoma
P/B = parathyroid to background ratio
P/T = parathyroid to thyroid ratioInternational Seminars in Surgical Oncology 2006, 3:30 http://www.issoonline.com/content/3/1/30
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nation of 99mTc-sestamibi scintigraphy and high
resolution neck US provides several diagnostic localiza-
tion advantages:
(a) more accurate information about PA localization
(orthotopic or ectopic site, deepness, etc)
(b) differentiation of solitary PA from multiple gland dis-
ease;
(c) evaluation of presence of co-existing nodular goiter [3-
8,14].
(d) furthermore, the use of SPECT improves sensitivity
and accuracy of the imaging procedure [22,23].
In our protocol, neck US was systematically combined
with  99mTc-sestamibi scintigraphy while SPECT was
reserved for patients with ectopic parathyroid glands or
incongruent  99mTc-sestamibi (positive)/US (negative)
results.
The first focused minimally invasive parathyroidectomy
protocol was developed by Norman in USA in 1997 [12]:
it consisted of a single-day, imaging and surgery
approach, with the patient injected with a 740–925 MBq
(20–25 mCi) of sestamibi and imaging obtained using a
dual-phase technique with focused parathyroidectomy via
a lateral neck access performed within 2–3 hours after
radiotracer administration. Norman's protocol is attrac-
tive from a cost-analysis perspective because 99mTc-sesta-
mibi scintigraphy and focused surgery are performed on
the same day using a single dose of 99mTc-sestamibi that is
sufficient for both planar scintigraphy and "focused' radi-
oguided surgery. However, Norman's protocol presents
practical disadvantages given the uncertainty of the scinti-
graphic results and differences between the minimally
invasive parathyroidectomy and BNE with respect to the
need for operating theatre time and efficient patient
scheduling. Indeed, this problem would be expected to be
even greater in geographic areas with a high prevalence of
nodular goiter so that a multiple-day imaging protocol
would be preferable [14]. The approach we use is a modi-
fied, multiple-day protocol: the first day imaging is
obtained using dual-tracer 99mTc-pertecnetate/99mTc-sesta-
mibi subtraction scintigraphy combined with high resolu-
tion neck US. The day of focused radioguided surgery is
usually performed within 1 week of imaging, using a low
37 MBq (1 mCi) 99mTc-sestamibi dose administered in the
operating room 10 minutes before operation. The 'low
sestamibi dose protocol' we use provides the two main
advantages of (a) less radiation exposure to the patient
and operating suite personnel (approximately 20-fold
lower than the "high sestamibi dose protocol" and (b)
fewer false negative results in PA exhibiting rapid 99mTc-
sestamibi wash-out [24].
Favorable results have been reported with both with Nor-
man's 'high sestamibi dose' protocol and our 'low sesta-
mibi dose' protocol with a success of intraoperative
detection of PA of 95% or more, without major intraoper-
ative surgical complications. It is reasonable to assume
Scintigraphy showing a left inferior parathyroid adenoma  located just beyond the thyroid left lobe shape, and in ante- rior planes at SPECT examination Figure 1
Scintigraphy showing a left inferior parathyroid adenoma 
located just beyond the thyroid left lobe shape, and in ante-
rior planes at SPECT examination. A = sequential acquisition 
of a set of 99mTc-sestamibi images, lasting 5 minutes each. B = 
99mTc-pertechenetate thyroid image. C = subtraction image 
showing a left inferior solitary parathyroid adenoma. D = 
Sestamibi SPECT images (left = axial; middle = sagittal; right = 
coronal) reconstructed by Butterworth filter with sub-opti-
mal parameters (cut-off = 0.40, order = 7); E = Sestamibi 
SPECT images (left = axial; middle = sagittal; right = coronal) 
reconstructed by Butterworth filter with optimal parameters 
(cut-off = 0.60, order = 7) depicting a left inferior parathy-
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that Norman's single-day protocol would be preferable in
patients with a low-likelihood of nodular goiter while the
multiple-day protocol would be preferable in areas with a
high prevalence of nodular goiter.
Another advantage of focused radioguided surgery is the
ability to perform minimally invasive neck exploration
under local anesthesia with early (also same-day) hospital
discharge [14]. Although attractive we prefer to offer this
approach to elderly and medically complex patients in
whom general anesthesia would contraindicated with
planned hospital on the 2nd postoperative day [25,26].
In conclusion, focused minimally invasive surgery is a safe
and effective approach for PHPT patients with a high
probability of a solitary PA. Preoperative accurate imag-
ing, based on 99mTc-sestamibi scintigraphy, is necessary.
Our data confirm that a low 37 MBq (1 mCi) 99mTc-sesta-
mibi dose administered in the operating room 10 minutes
before surgery is sufficient to successfully perform a
focused parathyroidectomy.
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